Biotech company Sarepta Therapeutics (NASDAQ:SRPT) reported Q1 CY2025 results beating Wall Street’s revenue expectations, ...

In cohort 6, subjects aged two years old at the time of treatment showed a mean expression of 93.87% of normal dystrophin ...

Sarepta Therapeutics shares were higher after J.P. Morgan reduced its December 2025 price target to $84 from $169 and maintained its overweight rating. The stock was up 4% to $39.55 Tuesday and is ...

Sarepta has submitted a request to the FDA to include the death case in Elevidys’ label, and the agency plans to review the ...

Shares of Sarepta Therapeutics cratered on Wednesday after the biopharmaceutical company trimmed its full-year forecast for ...

Taking center stage at the American Society of Gene and Cell Therapy meeting was the first-ever reported case of a ...

Biotech company Sarepta Therapeutics (NASDAQ:SRPT) reported in Q1 CY2025, with sales up 80.2% year on year to $744.9 million.

Sarepta Therapeutics Q1 2025 revenue beat expectations, but EPS missed, and cash reserves dropped significantly. Click here ...

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic ...

Since Elevidys' accelerated approval in 2023, experts have been clamoring for more data, particularly in older and ...

Sarepta Therapeutics shares are sinking after the company releases its first-quarter results after Tuesday's closing bell.

GlobalData analysts have tipped the global market for genomic therapies to balloon to almost $90 billion by 2030, driven by ...